LOGIN  |  REGISTER
Amneal Pharmaceuticals
Viking Therapeutics

So-Young to Report Third Quarter 2023 Financial Results on November 20, 2023

November 10, 2023 | Last Trade: US$0.84 0.05 5.95

BEIJING, Nov. 10, 2023 /PRNewswire/ -- So-Young International Inc. (NASDAQ: SY) ("So-Young" or the "Company"), the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, today announced that it will report its financial results for the third quarter ended September 30, 2023, before U.S. markets open on November 20, 2023.

So-Young's management will hold an earnings conference call on Monday, November 20, 2023, at 7:00 AM U.S. Eastern Time (8:00 PM on the same day, Beijing/Hong Kong Time). Dial-in details for the earnings conference call are as follows:

International:   +1-412-902-4272
China:           4001-201203
US:                  +1-888-346-8982
Hong Kong:   +852-301-84992
Passcode:        So-Young International Inc.

A telephone replay will be available two hours after the conclusion of the conference call through 23:59 U.S. Eastern Time, November 27, 2023. The dial-in details are:

International:   +1-412-317-0088
US:                  +1-877-344-7529
Passcode:       8166313

Additionally, a live and archived webcast of this conference call will be available at http://ir.soyoung.com.

About So-Young

So-Young is the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry. The Company presents users with reliable information through offering high quality and trustworthy content together with a multitude of social functions on its platform, as well as by curating medical aesthetic service providers that are carefully selected and vetted. Leveraging So-Young's strong brand image, extensive audience reach, trust from its users, highly engaging social community and data insights, the Company is well-positioned to expand both along the medical aesthetic industry value chain and into the massive, fast-growing consumption healthcare service market.

For more information, please contact:

So-Young

Investor Relations
Ms. Vivian Xu
Phone: +86-10-8790-2012
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Christensen

In China
Mr. Eric Yuan
Phone: +86-10-5900-1548
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. 

In US
Ms. Linda Bergkamp
Phone: +1-480-614-3004
Email: This email address is being protected from spambots. You need JavaScript enabled to view it. 

Viking Therapeutics

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB